The choice of these two classes of oral antidiabetic therapy relies on the mechanism of PAS-induced hyperglycemia, as the use of a DPP4-I or a GLP1RA can counterbalance the inhibition on endogenous GLP1 release induced by PAS. Here, DPP4 is linked to Hyperglycemia.